Amyloid - A

The Amyloid - A test generally refers to measurement of serum amyloid A, commonly abbreviated as SAA, in blood. Serum amyloid A is an acute-phase protein produced mainly by the liver. Its concentration can increase rapidly when the body responds to infection, inflammation, tissue injury or certain cancers. The test provides information about inflammatory activity but does not identify the exact cause by itself.

SAA is also important because prolonged or repeated elevation can contribute to AA amyloidosis. In this condition, fragments derived from serum amyloid A form abnormal deposits in organs and tissues. The kidneys are commonly affected, but deposits may also occur in the liver, spleen, digestive tract and other sites. Monitoring SAA can help doctors assess inflammatory control in patients at risk of this complication.

Benefits of the Test

• Measures serum amyloid A as a sensitive acute-phase inflammatory marker.
• Supports assessment of active inflammation or infection.
• Helps monitor chronic inflammatory and autoinflammatory diseases.
• Assists in evaluating the risk of secondary AA amyloidosis.
• May help monitor response to anti-inflammatory treatment.
• Provides additional information when interpreted with CRP, ESR and clinical findings.

Why Doctors Recommend This Test

A rheumatologist, physician, nephrologist or other specialist may recommend Serum Amyloid A testing when a patient has a chronic inflammatory condition associated with persistent acute-phase protein production. Examples can include rheumatoid arthritis, inflammatory bowel disease, chronic infections and inherited autoinflammatory disorders such as familial Mediterranean fever. The purpose may be to determine whether inflammation is adequately controlled and whether the patient remains at risk of AA amyloid deposition.

The test may also be requested during the evaluation of unexplained fever, inflammation or suspected infection. SAA can rise quickly in response to inflammatory stimuli, sometimes alongside C-reactive protein. However, many different illnesses can increase the value, so the result cannot distinguish bacterial infection from viral infection, autoimmune disease or another inflammatory cause without additional evidence.

In a patient with possible AA amyloidosis, symptoms may include protein in urine, swelling of the legs, reduced kidney function, persistent diarrhoea, weight loss, enlarged liver or spleen and fatigue. SAA testing can demonstrate ongoing inflammatory activity, but it cannot show whether amyloid deposits are already present. Tissue biopsy and amyloid typing may be required to confirm amyloidosis.

Preparation Before Test

Fasting is generally not required unless other tests collected at the same time need fasting. Tell the doctor about fever, recent infection, surgery, injury, vaccination, pregnancy, chronic inflammatory disease and all medicines or supplements. These factors may influence the result or its interpretation.

Do not stop anti-inflammatory, immune-modifying or other prescribed treatment unless instructed by the treating specialist. A routine venous blood sample is required. For disease monitoring, follow-up samples may be most useful when collected under similar clinical conditions and analysed using the same laboratory method.

Normal Reporting Time

Serum Amyloid A is a specialized inflammatory-marker assay and generally requires a few working days. The exact turnaround time depends on the testing schedule, collection centre, sample transportation, instrument availability and whether repeat analysis is necessary. Focus Diagnostics will provide the applicable reporting estimate during sample collection.

Who Should Take This Test?

• Patients with chronic inflammatory or autoinflammatory diseases.
• Individuals at risk of secondary AA amyloidosis.
• People with familial Mediterranean fever or another recurrent fever syndrome.
• Patients requiring monitoring of inflammatory disease activity or treatment response.
• Individuals with suspected AA amyloidosis and ongoing inflammation.
• Patients with unexplained inflammatory symptoms when recommended by a physician.
• Anyone specifically advised to undergo testing by a rheumatologist, nephrologist or other specialist.

Detailed Information

Serum amyloid A is normally present at a relatively low concentration. During an acute-phase response, production can increase markedly. Levels generally decline when the inflammatory stimulus resolves, making serial measurements potentially useful for monitoring disease activity. Persistent elevation suggests continuing inflammatory stimulation, although it does not specify the source.

AA amyloidosis differs from AL amyloidosis. AA amyloidosis results from prolonged elevation of serum amyloid A associated with chronic inflammation. AL amyloidosis results from abnormal immunoglobulin light chains produced by plasma cells. Serum Amyloid A testing does not diagnose AL amyloidosis and should not be confused with tests such as serum free light chains or immunofixation.

The result is interpreted using the laboratory's method-specific reference interval. SAA concentration may not always change in exactly the same way as CRP or ESR. Doctors may request all three markers because each provides a different view of the inflammatory response. Additional testing depends on the clinical concern and may include a complete blood count, kidney and liver function, urine protein, autoimmune tests, cultures or imaging.

If AA amyloidosis is suspected, confirmation generally requires demonstrating amyloid in tissue and determining the protein type. Biopsy specimens may be stained with Congo red and assessed using specialized typing methods. Kidney evaluation is particularly important because proteinuria can be an early manifestation.

Treatment focuses on controlling the underlying inflammatory disease so that SAA production remains as low as possible. The appropriate treatment may involve antimicrobial therapy, anti-inflammatory medicines, disease-modifying antirheumatic drugs or targeted biological treatments. Decisions should be made by the treating specialist, and trends over time are often more useful than a single measurement.